SynthesisOncotarget2016
MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- Key role of transcription factors network in proliferative vitreoretinal diseases development.Cell & bioscience · 2026Review
- Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer.British journal of cancer · 2026Article
- Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment.Journal of ovarian research · 2024Article
- High expression of SLC7A1 in high-grade serous ovarian cancer promotes tumor progression and is involved in MAPK/ERK pathway and EMT.Cancer medicine · 2024Article
- Cancer-associated fibroblasts in gynecological malignancies: are they really allies of the enemy?Frontiers in oncology · 2023Review
- CAFs orchestrates tumor immune microenvironment-A new target in cancer therapy?Frontiers in pharmacology · 2023Review
- GLIS1 in Cancer-Associated Fibroblasts Regulates the Migration and Invasion of Ovarian Cancer Cells.International journal of molecular sciences · 2022Article
- The Association of Suppressed Hypoxia-Inducible Factor-1 Transactivation of Angiogenesis With Defective Recovery From Cerebral Ischemic Injury in Aged Rats.Frontiers in aging neuroscience · 2021Article
- Identification of pathways and genes associated with meniscus degeneration using bioinformatics analyses.American journal of translational research · 2021Article
- MARCKSL1 promotes the proliferation, migration and invasion of lung adenocarcinoma cells.Oncology letters · 2020Article
- MARCKS and Lung Disease.American journal of respiratory cell and molecular biology · 2019Review
- A Unique Family of Neuronal Signaling Proteins Implicated in Oncogenesis and Tumor Suppression.Frontiers in oncology · 2019Review
- MARCKS protein overexpression is associated with poor prognosis in male breast cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- MicroRNA-138 inhibits SOX12 expression and the proliferation, invasion and migration of ovarian cancer cells.Experimental and therapeutic medicine · 2018Article
- Identification of pathways and genes associated with synovitis in osteoarthritis using bioinformatics analyses.Scientific reports · 2018Article
- Article
- Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.International journal of molecular sciences · 2017Article
- Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells.Blood cancer journal · 2017Article
- TGFβ1 in fibroblasts-derived exosomes promotes epithelial-mesenchymal transition of ovarian cancer cells.Oncotarget · 2017Article
- Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression.Molecular cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Cancer Genome Atlas network has revealed that the 'mesenchymal' epithelial ovarian cancer (EOC) subtype represents the poorest outcome, indicating a crucial role of stromal cancer-associated fibroblasts (CAFs) in disease progression. The cooperative role of CAFs in EOC metastasis has long been recognized, but the mechanisms of stromal CAFs activation are still obscure. Therefore, we carried out an integrative analysis to identify the regulator genes that are responsible for CAFs activation in microdissected tumor stroma profiles. Here, we determined that myristoylated alanine-rich C-kinase substrate (MARCKS) was highly expressed in ovarian stroma, and was required for the differentiation and tumor promoting function of CAFs. Suppression of MARCKS resulted in the loss of CAF features, and diminished role of CAFs in supporting tumor cell growth in 3D organotypic cultures and in murine xenograft model. Mechanistically, we found that MARCKS maintained CAF activation through suppression of cellular senescence and activation of the AKT/Twist1 signaling. Moreover, high MARCKS expression was associated with poor patient survival in EOC. Collectively, our findings identify the potential of MARCKS inhibition as a novel stroma-oriented therapy in EOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.